Companies /Healthcare

Vanda Pharmaceuticals Inc

NASDAQ: VNDA Biotechnology
$5.44
â–˛ $0.09 (+1.68%) today
Markets closed · 12:59am ET
Today · % change

Fundamentals

Market Cap
$323.5M
Profit Margin
-127.4%
Revenue (TTM)
$215.7M
EPS (TTM)
$-4.55
52-Week Range
$4 – $10
Street Target
$12.19

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company dedicated to creating treatments for a variety of health conditions with unmet medical needs around the globe. It markets HETLIOZ for non-24-hour sleep-wake disorders and Fanapt for schizophrenia. The company is also developing treatments for conditions like jet lag, insomnia, bipolar I disorder, and Parkinson’s disease psychosis, among others. Additionally, Vanda is working on therapies for gastroparesis, motion sickness, and certain dermatological and respiratory conditions. Founded in 2002, Vanda is based in Washington, D.C.

VNDA Coverage

9:11am ET
Health and Healthcare

Vanda Investors Can Sleep Easy With This FDA Approval

Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.

Chris Lange
9:50am ET
Health and Healthcare

Vanda Pharma Nails Midstage Gastroparesis Study

Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.

Chris Lange